Optimizing Immuno-Oncology Clinical Trials For Biotech Companies

Considerations for Developing Novel Treatments for Patients with Cancer

For biotech companies developing an immuno-oncology (IO) therapy, the complexity of oncology clinical trials takes on new dimensions.

Advances in translational science, new therapeutic platforms, unique mechanisms of action, and novel trial designs are just a few of the influences shaping the dynamic IO clinical trial space. IO-focused biotechs can still employ traditional oncology clinical trial parameters and processes, but considerations distinct to IO studies present unique scientific and operational challenges for even the most seasoned biotech executives. To help overcome these challenges and avoid unexpected risk, which can translate to significant safety concerns, time and cost, biotechs may benefit from supplementing their internal expertise with the help of a contract research organization (CRO) experienced in executing IO clinical trials. This white paper reviews the current IO landscape and considerations for biotech companies preparing for IO studies.